Abstract
BackgroundThe Measurement and Treatment Research to Improve Cognition Schizophrenia Consensus Cognitive Battery (MCCB) has also been proposed for use in clinical trials to assess cognitive deficits in patients with bipolar disorder (BD). The aim of this study was to evaluate cognitive function assessed by the MCCB in BD.MethodsA literature search of the PubMed, Embase, PsycINFO, SCI, Cochrane Library databases and the Cochrane Controlled Trials Register was conducted. Case reports, reviews and meta-analyses were excluded and a systematic review of the remaining studies of cognitive function in BD was carried out. The cognitive outcome measure was the MCCB, including 7 domains and overall cognition. A random-effects model was applied.ResultsEighty eight studies were initially identified. Seven clinical studies comprising a total of 487 patients and 570 healthy controls (HC) were included in the meta-analysis. Patients with BD performed worse than HC in overall cognition and processing speed with a large effect size of >0.8; with a medium effect size (0.5–0.8) in attention, working memory, verbal learning and visual learning; and with a small effect size (0.2–0.5) in reasoning and problem solving and social cognition.ConclusionPatients with BD performed worse than HC in overall cognition and all cognitive domains of the MCCB. Cognitive deficits in domains of processing speed and working memory are prominent in patients with BD. Our findings suggest that MCCB can be usefully applied in BD.
Highlights
Cognitive impairment in schizophrenia has been noted for more than a century and has been a focus of research interest from the 1980s onwards [1]
Seven clinical studies comprising a total of 487 patients and 570 healthy controls (HC) were included in the meta-analysis
Patients with bipolar disorder (BD) performed worse than HC in overall cognition and processing speed with a large effect size of >0.8; with a medium effect size (0.5–0.8) in attention, working memory, verbal learning and visual learning; and with a small effect size (0.2–0.5) in reasoning and problem solving and social cognition
Summary
Cognitive impairment in schizophrenia has been noted for more than a century and has been a focus of research interest from the 1980s onwards [1]. Cognitive impairment is an important clinical symptom in bipolar disorder, and it may be that measures which produce improvements in cognition could provide better functioning and quality of life in patients [4]. A consensus clinical battery, The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) has been developed with the purpose of showing practical utility, good test– retest reliability and especially potential sensitivity to treatments designed to improve cognitive function in the disorder [12]. The MATRICS Consensus Cognitive Battery (MCCB) has been recommended by the United States Food and Drug Administration (FDA) to assess cognitive impairment as the primary outcome measure in registry trials of schizophrenia [13]. The Measurement and Treatment Research to Improve Cognition Schizophrenia Consensus Cognitive Battery (MCCB) has been proposed for use in clinical trials to assess cognitive deficits in patients with bipolar disorder (BD). The aim of this study was to evaluate cognitive function assessed by the MCCB in BD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
